Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 10/20 | 0.66 |
| ▸ | MTOR | P42345 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | TACR2 | P21452 | 2/20 | 0.45 |
| ▸ | CTSL | P07711 | 3/20 | 0.44 |
| ▸ | CTSK | P43235 | 3/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | CTSB | P07858 | 2/20 | 0.44 |
| ▸ | CTSS | P25774 | 2/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6442131 | 0.93 | FPR2 (0.57) | FPR2MTORTP53POLBMAPT | |
| SCHEMBL6020374 | 0.91 | FPR2 (0.53) | FPR2MTORCTSLCTSKCTSB | |
| SCHEMBL6020534 | 0.90 | FPR2 (0.53) | FPR2CTSLCTSKCTSBCTSS | |
| SCHEMBL6020184 | 0.89 | FPR2 (0.51) | FPR2CTSLCTSKCTSBCTSS | |
| SCHEMBL6019649 | 0.87 | FPR2 (0.49) | FPR2MAPTCTSLCTSKCTSB | |
| SCHEMBL6020699 | 0.87 | FPR2 (0.68) | FPR2MAPTCTSLCTSKCTSB | |
| SCHEMBL6020284 | 0.87 | FPR2 (0.51) | FPR2 | |
| SCHEMBL6019541 | 0.85 | FPR2 (0.47) | FPR2MTORMAPTCTSLCTSK | |
| SCHEMBL6020507 | 0.85 | FPR2 (0.55) | FPR2TACR2 | |
| SCHEMBL6020927 | 0.83 | FPR2 (0.52) | FPR2TP53CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060252813-A1 | Apparatus for curing a composite laminate | JERINI AG (DE) | 2006-11-09 | — | — | US | claimed |
| EP-1433778-A1 | Use of nitriles as rotamase inhibitors | Jerini AG (DE) | 2004-06-30 | — | — | EP | claimed |
| EP-1433779-A1 | Use of nitriles as inhibitors of non-proteolytic enzymes | Jerini AG (DE) | 2004-06-30 | — | — | EP | claimed |
| US-20060252813-A1 | Apparatus for curing a composite laminate | JERINI AG (DE) | 2006-11-09 | — | — | US | disclosed |
| EP-1433778-A1 | Use of nitriles as rotamase inhibitors | Jerini AG (DE) | 2004-06-30 | — | — | EP | disclosed |
| EP-1433779-A1 | Use of nitriles as inhibitors of non-proteolytic enzymes | Jerini AG (DE) | 2004-06-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252813-A1 | Apparatus for curing a composite laminate | DHX29, HDHD5, DHRS9 | FPR2 3247/4885MTOR 4497/4885TP53 4859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.